Todd C. Davis - 09 May 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Executive Officer, Director
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol: LGND
Transactions as of: 09 May 2025
Net transactions value: +$1,000,456
Form type: 4
Filing time: 13 May 2025, 20:05:16 UTC
Previous filing: 06 Mar 2025
Next filing: 11 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Davis Todd C	Chief Executive Officer, Director	555 HERITAGE DRIVE, SUITE 200, JUPITER	By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis	13 May 2025	0001392029

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Purchase	$175,678	+1,680	+1.1%	$104.57	153,404	09 May 2025	Direct
transaction	LGND	Common Stock	Purchase	$241,150	+2,307	+1.5%	$104.53	155,711	09 May 2025	Direct	F1
transaction	LGND	Common Stock	Purchase	$583,629	+5,523	+3.5%	$105.67	161,234	09 May 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.